Thoracic Key

Lipid (mg/dL) MDF (%) HELP (%) DALI (%) DSA (%) IA (%) LDL-C 56–62 55–61 53–76 49–75 62–69 Triglycerides 37–49 20–53 29–40 26–60 34–49 HDL-C 25–42 5–17 5–29 4–17 9–27…

Fig. 11.1 Mechanism of action of the main lipid-lowering nutraceuticals More clinical research is needed to clarify the potential role in therapy of some interesting nutraceuticals with strong preclinical evidence…

(1) Department of Hypertension, Medical University of Lodz, Lodz, Poland (2) Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College…

© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_10 10. Other Possible Drug Combinations for Dyslipidemia Karam Kostner1   (1) Department of Cardiology, Mater Hospital Brisbane and University of Qld, St Lucia, QLD, Australia…

Trial Study population Dose of co-administered drug(s) Duration (median) Primary endpoint Results AIM-HIGH [12] n = 3414 Aged > 45 years, established CVD (documented stable CAD, cerebrovascular or carotid disease, or PAD)…

Fig. 7.1 Mechanism of action of statin and mipomersen. (a) Mipomersen specifically binds the apoB mRNA sequence to provide a substrate for RNase H, which hydrolyses the apoB mRNA strand…

© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_6 6. Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope? Stephen J. Nicholls1   (1) South Australian Health and Medical Research Institute and University of…